Lutetium-177 PSMA radionuclide treatment (Lu-PSMA) is  a therapy that is brand new prostate that is advanced. Lu-PSMA is  a molecule that is radioactive especially attaches to tissue with a high amounts  of PSMA on top associated with the cells. This enables the radioactivity becoming provided primarily towards the prostate cancer tissues wherever obtained distribute, while sparing more tissue that is regular. Past lightweight medical studies of Lu-PSMA demonstrated activity that is people that are promising advanced prostate cancer tumors.

This study that is randomised examine  through  a kinds of radiation treatment also known as cabazitaxel, that may be the typical therapy for lots more impressive range prostate cancer tumors whenever other treatment options posses stopped operating. Half the individuals will receive Lu-PSMA and 1 / 2 shall get cabazitaxel. This research will provide more info about the chance and advantages of Lu-PSMA weighed against cabazitaxel in men with prostate cancer. We plan  to enrol 200 people within the study that is scholarly Australia.


TheraP is a collaboration between ANZUP cancer tumors studies team and also  the Prostate cancer tumors first rung on the ladder toward Australia (PCFA) with support through  the Australian Nuclear Science and tech company (ANSTO), Endocyte, It’s a Bloke Thing, Movember and CAN4CANCER.